Evidence map›Paper›PMID 24513691›Full record

ArticleThe pharmacogenomics journal2014

Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.

F Loupakis, C Antoniotti, C Cremolini, W Zhang, D Yang, T Wakatsuki, P Bohanes, M Schirripa, L Salvatore, G Masi and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

F Loupakis1] U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy [2] Istituto Toscano Tumori (ITT), Firenze, Italy.
C Antoniotti1] U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy [2] Istituto Toscano Tumori (ITT), Firenze, Italy.
C Cremolini1] U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy [2] Istituto Toscano Tumori (ITT), Firenze, Italy.
W ZhangDepartment of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
D YangDepartment of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
T WakatsukiDepartment of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
P BohanesDepartment of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
M Schirripa1] U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy [2] Istituto Toscano Tumori (ITT), Firenze, Italy.
L Salvatore1] U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy [2] Istituto Toscano Tumori (ITT), Firenze, Italy.
G Masi1] U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy [2] Istituto Toscano Tumori (ITT), Firenze, Italy.
V RicciUnità di Oncologia, Istituto Scientifico San Raffaele, Milano, Italy.
F GrazianoMedical Oncology Unit, Hospital of Pesaro, Pesaro, Italy.
A RuzzoSection of Biochemistry and Molecular Biology, Department of Biomolecular Sciences, University of Urbino, Urbino, Italy.
L BenhaimDepartment of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
F Marmorino1] U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy [2] Istituto Toscano Tumori (ITT), Firenze, Italy.
Y NingDepartment of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
R El-KhoueiryDepartment of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
A Falcone1] U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy [2] Istituto Toscano Tumori (ITT), Firenze, Italy.
H-J LenzDepartment of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
University of Southern California · USAzienda Ospedaliera Universitaria Pisana · ITTumour Institute of Tuscany · ITUniversity of Urbino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The number of CA tandem repeats (CA)n in a highly polymorphic region of EGFR (epidermal growth factor receptor) intron 1 may affect gene transcription; the potential impact of allelic variants on the efficacy of cetuximab in metastatic colorectal cancer (mCRC) patients is debated for long. This study aimed at prospectively estimating the impact of EGFR intron 1 (CA)n variants on clinical outcome in KRAS exon 2 and BRAF wild-type chemo-refractory mCRC patients, receiving cetuximab and irinotecan. Variants presenting<and ⩾20 CA repeats were defined as short (S) and long (L), respectively. One hundred and fifteen patients were included. No differences in progression-free survival or overall survival were observed between L- and SS genotypes (hazard ratio (HR)=1.00 (95% confidence interval (CI): 0.67-1.50), P=0.991; HR=1.32 (95% CI: 0.81-2.16), P=0.261). Exploratory analyses adopting other cutoff values previously described led to similar results. This prospective study did not confirm any previous retrospective finding, reporting a predictive or prognostic effect of EGFR (CA)n repeats allelic variants in chemo-refractory mCRC patients receiving cetuximab and irinotecan.

Indexed as

IntronsAdultAgedAntibodies, Monoclonal, HumanizedCamptothecinCetuximabColorectal NeoplasmsErbB ReceptorsFemaleHumansIrinotecanMaleMiddle AgedNeoplasm MetastasisPolymorphism, GeneticProspective StudiesAntibodies, Monoclonal, HumanizedBRAF protein, humanCamptothecinCetuximabEGFR protein, humanErbB ReceptorsIrinotecanKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras Proteins

Identifiers

PMID24513691
OpenAlexW1965670364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.